MSB 1.34% $1.51 mesoblast limited

Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval, page-235

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,929 Posts.
    lightbulb Created with Sketch. 2059
    JB1975- the NEW DATA is not available in the public domain. You were correct - well done- on predicting the CRL.
    All we know is below. I believe you had cast doubt upon Prof Kurtzbergs potency assay- what would have needed to be added to give you certainty? Can you predict what they may have achieved scientifically?
    Something has changed- that's a fact



    New data from second potency assay provided to FDA, meeting scheduled Q1 CY2024.

    Graft versus Host Disease – Pediatric and Adult Indications
    • United States Food and Drug Administration (FDA) informed Mesoblast after its Type C meeting
    during the quarter that following additional consideration the available clinical data from its Phase 3
    study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License
    Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute
    graft versus host disease (SR-aGVHD).
    • Mesoblast intends to file the resubmission this quarter, potentially resulting in an approval for
    Ryoncil® (remestemcel-L) in the second half of CY2024.
    • Mesoblast will now focus on its original strategy to first gain pediatric approval for RYONCIL, followed
    by label extension in the larger adult population.


    Reg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.